HER3 is expressed in more than 80% of EGFR-mutant ... with EGFR-mutated NSCLC previously treated with at least one EGFR inhibitor and platinum-based chemo. It is also collaborating with AZ on ...

Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of breast cancer-specific survival. ...HER3 expression was... significantly associated with ...

HER3 is expressed in more than 80% of EGFR-mutant ... comparing it to chemo in the second-line setting after treatment with an EGFR inhibitor, with results due next year. Meanwhile, Daiichi ...

Key Findings: CS2011 (an EGFR/HER3 bispecific antibody), composed of anti-EGFR and anti-HER3 arms with balanced affinity, effectively and synergistically inhibits EGFR/HER3 downstream signaling ...

mice treated with a PD-1 inhibitor alone. In December 2024, Elevation Oncology nominated EO-1022 as its HER3 ADC development candidate for the treatment of HER3-expressing solid tumors including ...

From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally ...

In addition, we continue to develop our HER3 ADC EO-1022 for the treatment ... EO-3021 in combination with dostarlimab, a PD-1 inhibitor, in the first-line setting and with ramucirumab, a VEGFR2 ...